Personalis, Inc. (PSNL)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
$15.79+0.25%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
QuarterlyIQ Insights · PSNL
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 15.5% |
| Our one-year growth estimate | diamond | 48.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 32.6 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 12 industry peers · Company calendar date is not available
PSNL — divestiture
Dated 2026-10-06
Other Events. As previously disclosed, on July 20, 2026, Personalis, Inc., a Delaware corporation (“ Personalis ” or the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Tempus AI, Inc., a Nevada corporation (“ Tempus ” or “ Parent ”), Aviary Development, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (“ Merger Sub I ”), and Toucan Development, LLC, a Nevada limited liability company and a direct, wholly owned subsidiary…
Why it matters: Personalis holders are set to get Tempus stock, with a capped exchange ratio. The deal also names a Tempus share price tied to a Personalis right to end it.
Watch forThe final exchange ratio is set at or near the 0.3356 cap, and Tempus shares stay at or above $46 through closing.
Also watch forTempus shares fall below $46, and Personalis uses its right to end the deal. Or the final exchange ratio falls below the 0.3356 cap.
Why it matters: Q2 revenue rose 30% year over year, but Q1 revenue was lower than a year earlier. A Q3 increase would show growth continued.
Supportive ifQ3 total revenue exceeds Q2's $22.4 million.
Worry ifQ3 total revenue is $22.4 million or less.
Why it matters: The 8-K summary says Personalis reported an event tied to the merger agreement, but gives few details. The full filing can clarify its effect on the deal.
Watch forA full filing or company statement explains the October 6 event. It confirms the merger agreement remains in force.
Also watch forA filing states the event changed key deal terms, ended the agreement, or added a new closing barrier.
Why it matters: Clinical revenue reached $2.6 million in Q2, while management said 2026 clinical revenue would rise more than 500%. Q3 results test that growth path.
Supportive ifQ3 clinical revenue tops $2.6 million and clinical test volume exceeds Q2's 10,384 tests.
Worry ifQ3 clinical revenue is $2.6 million or less, or test volume falls below 10,384.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$117 on $10,000 · ±1.2% | How much price usually moves either way. |
| Bad day | $838 loss on $10,000 · 8.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,520 loss on $10,000 · 55.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.